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Abstract Here we report that the widely used protein kinase C
inhibitors, bisindolylmaleimide I and IX, are potent inhibitors of
glycogen synthase kinase-3 (GSK-3). Bisindolylmaleimide I
and IX inhibited GSK-3 in vitro, when assayed either in cell
lysates (IC50 360 nM and 6.8 nM, respectively) or in GSK-3L
immunoprecipitates (IC50 170 nM and 2.8 nM, respectively)
derived from rat epididymal adipocytes. Pretreatment of
adipocytes with bisindolylmaleimide I (5 WM) and IX (2 WM)
reduced GSK-3 activity in total cell lysates, to 25.1 þ 4.3% and
12.9 þ 3.0% of control, respectively. By contrast, bisindolyl-
maleimide V (5 WM), which lacks the functional groups present
on bisindolylmaleimide I and IX, had little apparent effect. We
propose that bisindolylmaleimide I and IX can directly inhibit
GSK-3, and that this may explain some of the previously
reported insulin-like effects on glycogen synthase activity.
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1. Introduction.
The bisindolylmaleimide derivatives of staurosporine are
widely used as speci¢c inhibitors of protein kinase C (PKC)
isoforms. Bisindolylmaleimide I (also known as GF 109203x)
and IX (also known as Ro 31-8220) are the most commonly
used PKC inhibitors [1^3]. In contrast, bisindolylmaleimide V
does not inhibit PKC isoforms and is used as a negative con-
trol as it lacks the important functional groups present on
bisindolylmaleimide I and IX [4].
Recently, several additional pharmacological e¡ects of bis-
indolylmaleimide IX have been reported. Beltman et al. [5]
showed that bisindolylmaleimide IX strongly stimulates the
activity of c-Jun-N-terminal kinase (JNK) and the expression
of c-jun, while it inhibits growth factor-stimulated mitogen-
activated protein (MAP) phosphatase-1 (MKP-1) gene expres-
sion in Rat-1 ¢broblasts in a PKC-independent manner. In
contrast, bisindolylmaleimide I had no e¡ect on these signal-
ling components.
A later report by this group showed that bisindolylmale-
imide IX induced the phosphorylation and possible activation
of p38 MAPK, as well as phosphorylation of the activator
protein-1 (AP-1) family member c-Jun, and a concomitant
increase in AP-1 activity [6]. Subsequently, Standaert et al.
[7] reported that bisindolylmaleimide IX activates JNK and
increases glycogen synthase activity in primary rat adipocytes,
independently of PKC inhibition. The authors concluded that
JNK rather than PKC, protein kinase B or ERK1/2, was
involved in the activation of glycogen synthase by bisindolyl-
maleimide IX.
Glycogen synthase is a key enzyme that catalyses the incor-
poration of the glycosyl residue of UDP-glucose into glyco-
gen, and its activity is regulated by multisite phosphorylation.
In particular, glycogen synthase kinase-3 (GSK-3) phospho-
rylates and inhibits the enzyme [8,9]. Insulin has been
proposed to stimulate glycogen synthase by promoting an
inhibition of GSK-3 [10] and/or activation of protein phos-
phatase-1 [11], resulting in a net dephosphorylation of glyco-
gen synthase.
In our investigations of the mechanism by which insulin
regulates glycogen synthase activity in rat adipocytes, we
found that bisindolylmaleimide I and IX were potent inhibi-
tors of GSK-3. We propose that this may be the likely mech-
anism by which bisindolylmaleimide IX stimulates glycogen
synthesis.
2. Materials and methods
2.1. Materials
Male Wistar rats (160^210 g) were fed ad libitum on a stock diet
(CRM; Bioshore, Manea, Cambs., UK). Bisindolylmaleimide I (GF
109203x) and V were from Calbiochem (Nottingham, UK), bisindo-
lylmaleimide IX (Ro 31-8220) was from Alexis Corporation (UK) and
the anti-GSK-3L monoclonal antibody was purchased from Trans-
duction Laboratories (Becton Dickinson, UK). All other reagents
were as described [12].
2.2. Preparation and incubation of epididymal fat cells
Adipocytes were isolated from the epididymal fat pads of Wistar
rats as described previously [13]. Cells (150^250 mg dry cell weight)
were extracted in 1 ml of ice-cold 50 mM Tris (pH 7.5) containing
1 mM EDTA, 120 mM NaCl, 50 mM NaF, 40 mM L-glycerophos-
phate, 1 mM benzamidine, 1% NP40, 1 WM microcystin and 1 Wg/ml
each of pepstatin, leupeptin and antipain. Lysates were centrifuged
twice at 10 000Ug for 10 min at 4‡C prior to use, and the infranatant
was taken for measurement of protein kinase activity.
2.3. GSK-3 activity assay
GSK-3 activity was measured in cell lysates and in GSK-3L immu-
noprecipitates. GSK-3L was immunoprecipitated from cell lysates by
tumbling with 4 Wl of anti-GSK-3L monoclonal antibody and 3.75 mg
protein A-Sepharose for 2 h at 4‡C. The resulting immunoprecipitates
were washed three times in kinase assay bu¡er (20 mM HEPES, pH
7.5, 20 mM L-glycerophosphate and 1 mM EDTA) and ¢nally resus-
pended in 300 Wl of kinase assay bu¡er containing 0.1% mercapto-
ethanol and 2.5 WM cAMP-dependent protein kinase inhibitor peptide
(IP20). The activity of GSK-3 was measured in duplicate in 20 Wl of
cell lysate or 20 Wl of GSK-3L immunoprecipitate using the synthetic
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peptide substrate RRAAEELDSRAGS(P)PQL (0.71 mg/ml) [14] in
the absence or in the presence of the GSK-3 inhibitor, lithium chlo-
ride (50 mM) [15]. The assay was terminated after 15 min incubation
with [Q- 32P]ATP by spotting onto P81 ion-exchange paper. The paper
was washed four times in 0.6% phosphoric acid and bound radio-
activity quanti¢ed by scintillation counting. Phosphorylation of pep-
tide by adipocyte lysates and by GSK-3L immunoprecipitates was
essentially completely inhibited by lithium chloride. The average ac-
tivity of GSK-3 in the extracts was 1220 þ 144 pmol peptide phos-
phorylated/min/g dry weight of adipocytes (n = 11). The average ac-
tivity of GSK-3L in immunoprecipitates was 276 þ 54 pmol peptide
phosphorylated/min/g dry weight of adipocytes (n = 11).
3. Results
3.1. Direct e¡ects of bisindolylmaleimide I and IX on GSK-3
activity
To investigate whether bisindolylmaleimide I and IX a¡ect
GSK-3 activity, freshly isolated primary adipocytes were ex-
tracted and GSK-3 activity was subsequently measured in
total lysates and in GSK-3L immunoprecipitates. Bisindolyl-
maleimide I inhibited GSK-3 activity with an IC50 of 360 nM
in total lysates and an IC50 of 190 nM in GSK-3L immuno-
precipitates (Fig. 1A). Bisindolylmaleimide IX was much
more potent in inhibiting GSK-3 activity in total lysates
(IC50 = 6.8 nM) and in GSK-3L immunoprecipitates
(IC50 = 2.8 nM, Fig. 1B). In contrast, bisindolylmaleimide V
(5 WM) had no major e¡ect on GSK-3 activity in total lysates
(85.6 þ 9%, n = 7) and immunoprecipitates (98.3 þ 12.5%,
n = 6).
3.2. E¡ect of bisindolylmaleimide I, V and IX on GSK-3
activity in primary adipocytes
As expected, incubation of intact adipocytes with the inhib-
itors bisindolylmaleimide I and IX strongly inhibited GSK-3
Fig. 1. E¡ect of bisindolylmaleimide I and IX on GSK-3 activity in
total extracts and in immunoprecipitates. Total lysates (F) or GSK-
3L immunoprecipitates (R) from rat epididymal adipocytes were in-
cubated for 5 min at 30‡C with di¡erent concentrations of bisindol-
ylmaleimide I (A) and bisindolylmaleimide IX (B) before addition
of [Q-32P]ATP and substrate peptide. The assay was terminated after
15 min incubation with [Q-32P]ATP by spotting onto P81 ion-ex-
change paper. Data (mean þ S.E.M., 3^5 observations) are expressed
as percentage of GSK-3 activity in the absence of inhibitor.
Fig. 2. E¡ect of various bisindolylmaleimides on GSK-3 activity in
rat epididymal adipocytes. Cells were incubated with vehicle
(DMSO), bisindolylmaleimide I (bis I, 5 WM), V (bis V, 5 WM) and
IX (bis IX, 2 WM) for 5 min at 37‡C prior to addition of insulin
(ins, 83 nM). Cells were extracted after a 10 min incubation and
GSK-3 activity was subsequently measured in total cell lysates (A)
and in GSK-3L immunoprecipitates (B) as described in the legend
to Fig. 1. Data (mean þ S.E.M., 3^5 observations) are expressed as
percentage of GSK-3 activity in the absence of inhibitor.
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activity, when subsequently assayed in total lysates (Fig. 2A).
In contrast, bisindolylmaleimide V had no e¡ect. Insulin in-
hibited GSK-3 activity to 59 þ 6% of control and the e¡ect
was not additive to bisindolylmaleimide I- and IX-induced
GSK-3 inhibition (Fig. 2A). When GSK-3L was immunopre-
cipitated following extraction of the cells, the inhibitory e¡ect
of bisindolylmaleimide I was lost (Fig. 2B). In contrast, the
more potent inhibitor, bisindolylmaleimide IX, still reduced
GSK-3 activity to 59 þ 9% of control.
4. Discussion
In this study we show that GSK-3, a key kinase in insulin-
induced activation of glycogen synthase, is potently and di-
rectly inhibited by the PKC inhibitors bisindolylmaleimide I
and IX. Both bisindolylmaleimides strongly inhibited GSK-3
activity when added directly to cell lysates and GSK-3L im-
munoprecipitates. Bisindolylmaleimide IX was the more po-
tent inhibitor of GSK-3 activity, with an approximately 100
times lower IC50 value than bisindolylmaleimide I. Bisindolyl-
maleimide IX is an equally potent inhibitor of both GSK-3
and PKC (IC50 values for GSK-3 of 3^7 nM found in this
study compared to an IC50 of 5 nM for PKC [16]).
It is likely that bisindolylmaleimide I and IX compete re-
versibly with ATP for binding to the nucleotide-binding site of
GSK-3, as proposed for PKC [1]. The loss of the inhibitory
e¡ect of the agents during immunoprecipitation of GSK3L
from cells previously exposed to them is compatible with
this. Bisindolylmaleimide I had little e¡ect on insulin-induced
inhibition of GSK-3, under conditions where it would be ex-
pected to potently inhibit PKC activity [1]. This strongly sug-
gests that PKC, although it has previously been implicated in
GSK-3 regulation [17,18], is not involved in this process. This
is consistent with observations that insulin-induced inhibition
of GSK-3 in mouse 10T1/2 ¢broblasts was una¡ected by bis-
indolylmaleimide IX, whereas Wingless-induced inactivation
was blocked [19].
Many of the recently reported stimulatory e¡ects of bisin-
dolylmaleimide IX [5^7] may be explained by its ability to
inhibit GSK-3. Bisindolylmaleimide IX increases glycogen
synthase activity in adipocytes. This e¡ect was attributed to
the ability of bisindolylmaleimide IX to stimulate JNK activ-
ity [7]. Given the observations in the present study, it is more
simply explained by inhibition of GSK-3, since GSK-3, which
has a high activity in resting cells, is able to phosphorylate
and inactivate glycogen synthase. In contrast to insulin, bisin-
dolylmaleimide IX was shown to stimulate glycogen synthase
activity in a phosphatidyl inositol-3 kinase (PI3 kinase)-inde-
pendent manner [7], which is consistent with a direct inhib-
itory e¡ect on GSK-3.
Bisindolylmaleimide IX and insulin have additive e¡ects on
glycogen synthase activity [7]. Similar results have recently
been found with lithium, a speci¢c GSK-3 inhibitor, and in-
sulin [20]. This contrasts with the e¡ects of insulin and bisin-
dolylmaleimide IX on GSK-3 inhibition, which were not ad-
ditive (Fig. 2). This apparent discrepancy may be explained by
the ability of insulin to activate protein phosphatase-1 [21],
and hence the dephosphorylation of glycogen synthase by a
mechanism independent of GSK-3.
Several groups have reported that bisindolylmaleimide IX
activates JNK in cells in a PKC-independent manner [5,7].
Activation of JNK by insulin is blocked by wortmannin in
CHO cells expressing the insulin receptor and is likely, there-
fore, to be downstream of PI3 kinase activation [22]. This
raises the possibility that inhibition of GSK-3 activity may
lead, presumably indirect, to the activation of JNK. This hy-
pothesis is consistent with the observation that the bisindolyl-
maleimide IX- and insulin-stimulated JNK activation in rat
adipocytes are not additive [7]. It requires rigorous testing,
particularly as bisindolylmaleimide IX is known to inhibit
other protein kinases, such as MAPKAP kinase and p70S6
kinase [16]. However, it should be noted that these particular
kinases are unlikely to be involved as insulin and bisindolyl-
maleimide IX have opposite e¡ects on their activity.
One of the substrates of JNK is c-Jun, which forms part of
the activating protein-1 complex (AP-1 complex), and is phos-
phorylated by JNK on two regulatory sites Ser-63 and Ser-73.
Phosphorylation of these sites transactivates c-Jun, and may
also explain the increased c-jun expression induced by bisin-
dolylmaleimide IX [5]. Stimulation of AP-1 activity in re-
sponse to bisindolylmaleimide IX is likely, therefore, to be
the result of increased c-Jun synthesis and/or phosphorylation
of c-Jun on Ser-63 and Ser-73 by increased JNK activity [6].
However, GSK-3 phosphorylates c-Jun on three sites in a
region proximal to the DNA-binding domain (residues 227^
252), resulting in decreased c-Jun DNA binding and transcrip-
tional activity [23]. Indeed, transfection experiments have
shown that AP-1 activity is inhibited by co-expression of
GSK-3 [24]. Inhibition of GSK-3 activity by bisindolylmale-
imide IX might therefore abolish this negative restraint, there-
by increasing c-Jun/AP-1 activity.
In summary, we have demonstrated that both bisindolyl-
maleimide I and IX are potent and direct inhibitors of
GSK-3. Our results raise the possibility that some of the
insulin-like e¡ects of bisindolylmaleimide IX, in particular
the activation of glycogen synthase, may be the result of the
ability of these compounds to inhibit GSK-3.
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